Aneuploidy Rates in IVF Patients ≤34 Years Old Based on the Indication for Preimplantation Genetic Diagnosis Aneuploidy Screening (PGD-AS)

Abstract

Background: Studies on the rate of aneuploidy in IVF patients have shown varied results, ranging from 50% to 90% of the embryos. Despite this compelling data, controversy remains regarding which patients, if any, benefit from PGD-AS.Objective: We compared the rates of aneuploidy in young IVF patients based on the indication for PGD-AS to further elucidate which patient groups benefit most from this technique.Design: Cohort case report.Materials and Methods: All patients with female age ≤34 years undergoing PGD-AS at the ART Reproductive Center from January 2007 through November 2007 were divided into categories based on their indication for PGD-AS: recurrent pregnancy loss (RPL), recurrent implantation failure (RIF), gender determination (GD), and egg donor recipient cycles (ED).Tabled 1Age (n = 46)≤34 yrsGD (n = 17)49.6 (59/119)RIF (n = 4)40 (14/35)RPL (n = 12)27.9 (29/104)ED (n = 13)51.2 (80/156) Open table in a new tab Tabled 1Age (n = 46)≤34 yrsGD vs. RIF.342GD vs. RPL.001GD vs. ED.597ED vs. RIF.297ED vs. RPL.001RIF vs. RPL.207 Open table in a new tab There was no significant difference in aneuploidy rates in GD patients compared with patients who underwent PGD-AS for ED. Women with a history of RPL had a significantly higher rate of aneuploidy than patients who requested PGD-AS for GD or ED. There was no significant difference in aneuploidy rates between patients in the ROF and RPL groups.Conclusions: The nonsignificant difference between the RIF and RPL groups may be biased by the small sample sizes of both groups. In women ≤34 years old with RIF, the percentage of aneuploidy is the same as that for the GD and ED groups. Women ≤34 years of age with RPL showed a significantly higher rate of aneuploidy compared with those who had PGD-AS for GD and ED cycles, suggesting that this subset of patients may benefit from PGD-AS. Aneuploidy screening remains the only way to determine whether an embryo, regardless of its morphology, possesses a balanced set of chromosomes and is therefore capable of initiating a sustainable pregnancy. Background: Studies on the rate of aneuploidy in IVF patients have shown varied results, ranging from 50% to 90% of the embryos. Despite this compelling data, controversy remains regarding which patients, if any, benefit from PGD-AS. Objective: We compared the rates of aneuploidy in young IVF patients based on the indication for PGD-AS to further elucidate which patient groups benefit most from this technique. Design: Cohort case report. Materials and Methods: All patients with female age ≤34 years undergoing PGD-AS at the ART Reproductive Center from January 2007 through November 2007 were divided into categories based on their indication for PGD-AS: recurrent pregnancy loss (RPL), recurrent implantation failure (RIF), gender determination (GD), and egg donor recipient cycles (ED). There was no significant difference in aneuploidy rates in GD patients compared with patients who underwent PGD-AS for ED. Women with a history of RPL had a significantly higher rate of aneuploidy than patients who requested PGD-AS for GD or ED. There was no significant difference in aneuploidy rates between patients in the ROF and RPL groups. Conclusions: The nonsignificant difference between the RIF and RPL groups may be biased by the small sample sizes of both groups. In women ≤34 years old with RIF, the percentage of aneuploidy is the same as that for the GD and ED groups. Women ≤34 years of age with RPL showed a significantly higher rate of aneuploidy compared with those who had PGD-AS for GD and ED cycles, suggesting that this subset of patients may benefit from PGD-AS. Aneuploidy screening remains the only way to determine whether an embryo, regardless of its morphology, possesses a balanced set of chromosomes and is therefore capable of initiating a sustainable pregnancy.